Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM – Cardiovascular Business Posted on August 31, 2026 By Malcolm Knoll No Comments on Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM – Cardiovascular Business Aficamten: Potentially Groundbreaking Treatment for Nonobstructive HCM Aficamten shows potential to be the first FDA-approved treatment for nonobstructive HCM, as reported by Cardiovascular Business. Business